Bio-Techne Corporation
IT ˙ BIT ˙ US09073M1045
54,00 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1TECH / Bio-Techne Corporation
InstitutionMaverick Capital Ltd
Latest Disclosed Ownership4,739,721 shares
Latest Disclosed Value $ 247,697,819
Maverick Capital Ltd reports 23.08% increase in ownership of 1TECH / Bio-Techne Corporation

On May 15, 2026 - Maverick Capital Ltd filed a 13F-HR form disclosing ownership of 4,739,721 shares of Bio-Techne Corporation (IT:1TECH) valued at $255,944,934 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 3,850,923 shares of Bio-Techne Corporation. This represents a change in shares of 23.08% during the quarter. The current value of the position is $255,944,934 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BIO-TECHNE COM 09073M104 4,739,721 888,798 23.08 247,698 9.37 2.8569
2026-02-13 2025-12-31 13F BIO-TECHNE COM 09073M104 3,850,923 838,269 27.82 226,473 35.13 2.4310
2025-11-14 2025-09-30 13F BIO-TECHNE COM 09073M104 3,012,654 3,012,654 167,594 2.2400
2025-08-14 2025-06-30 13F BIO-TECHNE COM 09073M104 0 -522,897 -100.00 0 -100.00
2025-05-15 2025-03-31 13F BIO-TECHNE COM 09073M104 522,897 522,897 30,657 0.5419
2021-08-18 2021-06-30 13F/A-1 BIO-TECHNE COM 09073M104 0 -1,526 -100.00 0 -100.00
2021-05-17 2021-03-31 13F BIO-TECHNE COM 09073M104 1,526 -660 -30.19 583 -15.99 0.0054
2021-02-16 2020-12-31 13F BIO-TECHNE COM 09073M104 2,186 1,479 209.19 694 296.57 0.0111
2020-11-16 2020-09-30 13F BIO-TECHNE COM 09073M104 707 318 81.75 175 69.90 0.0033
2020-08-14 2020-06-30 13F BIO-TECHNE COM 09073M104 389 -8,019 -95.37 103 -93.54 0.0022
2020-05-19 2020-03-31 13F/A-1 BIO-TECHNE COM 09073M104 8,408 -821 -8.90 1,594 -21.32 0.0337
2020-05-15 2020-03-31 13F BIO-TECHNE COM 09073M104 8,408 -821 1,594 33,622.2229
2020-02-14 2019-12-31 13F BIO TECHNE COM 09073M104 9,229 9,229 2,026 0.0295
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.